SWK Holdings Business Summary

SWK Holdings Corp (SWKH) is a specialized finance company that provides non-dilutive, minimally dilutive capital solutions to small- and mid-sized commercial-stage life science and healthcare companies. The company generates revenue primarily through interest income and fees derived from its Finance Receivables segment, which utilizes structured debt, royalty monetization, and hybrid financing transactions to support biotechnology, medical device, and pharmaceutical firms. Its secondary segment, Pharmaceutical Development, focuses on clinical development and manufacturing services, leveraging its proprietary Peptelligence drug delivery platform. As of February 2026, SWK Holdings is in the final stages of a definitive merger agreement to be acquired by Runway Growth Finance Corp (RWAY), a move intended to scale its healthcare portfolio. Within the specialty finance market, SWKH competes with firms such as Atlanticus Holdings (ATLC), Velocity Financial (VEL), and OppFi (OPFI), positioning itself as a niche leader by offering deep domain expertise and flexible capital structures tailored specifically to the regulatory and commercial cycles of the healthcare industry. Leadership is currently headed by President and CEO Jody Staggs, who has been with the firm since 2015 and previously held senior investment roles at Annandale Capital and Highland Capital Management. Staggs, a CFA charterholder, is supported by Chief Financial Officer Adam C. Rice, a CPA who joined in July 2024 with over 18 years of experience from Park Cities Asset Management and Ernst & Young. The company’s strategic direction is overseen by Chairman Michael Weinberg and a board that includes Jerry Albright, former CIO of the Teacher Retirement System of Texas, and Laurie Dotter. A significant portion of the company’s equity is held by institutional investors, most notably Carlson Capital L.P., which has been a pivotal stakeholder in facilitating the pending acquisition by Runway Growth Finance. This leadership team is recognized for its disciplined underwriting and ability to originate high-yield, senior-secured credit opportunities across the global life sciences sector.